Professional Role and Current Responsibilities
Ram Aiyar, Ph.D., MBA serves as the President, Chief Executive Officer, and a Director of Korro Bio, Inc., a role he has held since at least November 2020 following the completion of a merger that shaped Korro Bio’s current entity. His executive positions are formally documented in multiple SEC filings throughout 2023 and 2024, affirming his leadership and signatory authority for the company’s key regulatory documents.
At Korro Bio, Dr. Aiyar is responsible for guiding the company's strategic direction and execution, with explicit powers and duties tied to the President and CEO positions. His official capacity as a director further positions him involved in governance matters, confirming his integral role in decision-making at Korro Bio.
Educational Background
Dr. Aiyar holds a Ph.D. in Electrical and Computer Engineering from Drexel University, complemented by an MBA in Finance and Business Strategy from INSEAD. He also has advanced degrees including an M.S. in Electrical and Computer Engineering, and a Bachelor of Engineering in Electronics from the University of Dayton. His education combines rigorous scientific training with high-level business acumen, supporting his leadership in technology-driven biotech ventures.
Career Trajectory and Relevant Experience
Prior to his tenure at Korro Bio, Dr. Aiyar co-founded and served as Chief Financial Officer (CFO) and Chief Business Officer (CBO) at Corvidia Therapeutics, a biopharmaceutical company focused on innovative cardiovascular therapies. His leadership was a key factor in Corvidia’s successful acquisition by Novo Nordisk for $2.1 billion. This transaction underscores his experience in scaling biotech startups and managing high-value corporate developments.
Earlier in his career, he began as a researcher with Janssen Pharmaceuticals' immunology group, reflecting a strong foundation in biomedical sciences and industry research. He also held positions in corporate development, finance, and strategic roles, further broadening his expertise in business operations within the pharmaceutical and biotechnology sectors.
Industry Expertise and Scientific Focus
Dr. Aiyar leads Korro Bio in advancing RNA editing therapeutics, a novel class of genetic medicines. Korro Bio’s proprietary platform focuses on precise and transient RNA modifications, targeting correction of disease-causing mutations without permanent DNA alteration, which suggests a risk-mitigated approach to genetic medicine.
He communicates actively on the potential of ADAR-based RNA editing and its capacity to modulate protein function and correct mutations, positioning Korro Bio at the forefront of RNA editing innovation. Notably, Korro Bio engages in a significant collaboration with Novo Nordisk to expand RNA editing applications in cardiometabolic diseases, evidencing Dr. Aiyar’s ability to leverage partnerships with established pharmaceutical leaders to extend the reach and impact of Korro’s pipeline.
Recent media and industry engagements highlight his thought leadership on RNA editing technology, underscoring his role in driving innovation in a rapidly evolving therapeutic arena. His statements emphasize Korro’s transition from preclinical to clinical stages, maintaining a focused “3-2-1” strategy amid operational challenges such as workforce reductions, indicative of adaptive management under his leadership.
Company Performance and Strategic Positioning
Under Dr. Aiyar's leadership, Korro Bio is transitioning through critical phases of biopharmaceutical development, moving its RNA editing platform closer to clinical application. The company’s strategic partnership with Novo Nordisk reinforces its credibility and resource access to tackle rare and prevalent diseases through RNA therapeutics. His experience in finance and strategic corporate development aligns with Korro Bio’s efforts to navigate capital markets and investor relations, as evidenced by his role in signing numerous SEC filings and financial disclosures.
Relevant Public Profile and Communication Channels
- LinkedIn: [https://www.linkedin.com/in/ram-aiyar-1940005](https://www.linkedin.com/in/ram-aiyar-1940005)
- Korro Bio Executive Biography: Confirms his roles, educational credentials, and prior leadership experience.
- Multiple industry interviews and presentations (e.g., BiotechTV, LifeSciVC, Timmerman Report) portray him as an articulate advocate for RNA editing therapeutics, reinforcing his prominence within the biotech innovation ecosystem.
This profile synthesizes Dr. Aiyar’s scientific expertise, executive leadership, and strategic business capabilities. His unique blend of technical and financial experience is a critical asset for Korro Bio as the company advances RNA editing medicines towards commercialization and broader therapeutic impact.
